Allarity Therapeutics (ALLR) said Thursday it reached a final settlement with the US Securities and Exchange Commission regarding the investigation into its past disclosures about interactions with the US Food and Drug Administration concerning its 2021 application for Dovitinib.
Under the settlement, which follows a preliminary agreement in January, Allarity said it agreed to an administrative cease-and-desist order without admitting or denying any wrongdoing.
The company said previously that it agreed to pay a one-time civil penalty of $2.5 million to resolve the investigation. The amount does not affect its outlook, Allarity said, adding that it continues to expect its cash position to support operations into 2026.
Shares of Allarity were up about 2% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。